Share on StockTwits

Shares of Prothena Co. PLC (NASDAQ:PRTA) have been given a consensus rating of “Buy” by the nine brokerages that are currently covering the company, StockRatingsNetwork.com reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $37.44.

Shares of Prothena Co. PLC (NASDAQ:PRTA) opened at 21.49 on Thursday. Prothena Co. PLC has a 52-week low of $16.71 and a 52-week high of $49.24. The stock’s 50-day moving average is $19.77 and its 200-day moving average is $26.42. The company’s market cap is $588.3 million.

Prothena Co. PLC (NASDAQ:PRTA) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.06 earnings per share (EPS) for the quarter. The company had revenue of $15.10 million for the quarter. On average, analysts predict that Prothena Co. PLC will post $-0.71 earnings per share for the current fiscal year.

In other Prothena Co. PLC news, Insider Karin L. Walker unloaded 2,500 shares of Prothena Co. PLC stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $20.74, for a total value of $51,850.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

PRTA has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Prothena Co. PLC from a “neutral” rating to an “outperform” rating in a research note on Tuesday, August 5th. They now have a $20.00 price target on the stock. Analysts at Oppenheimer initiated coverage on shares of Prothena Co. PLC in a research note on Thursday, July 10th. They set an “outperform” rating and a $40.00 price target on the stock.

Prothena Corporation PLC is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.